Number of the records: 1
Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment
- 1.
SYSNO ASEP 0569862 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment Author(s) Mortazavi, S. M. J. (IR)
Nowroozi, S. (IR)
Haghani, M. (IR)
Zarrini-Monfared, Z. (IR)
Gheisari, F. (IR)
Sihver, Lembit (UJF-V)Number of authors 6 Article number 740 Source Title Cancers (Basel). - : MDPI
Roč. 15, č. 3 (2023)Number of pages 9 s. Publication form Online - E Language eng - English Country CH - Switzerland Keywords nuclear medicine ; radioiodine therapy ; probiotic bacteria ; iodine-131 OECD category Radiology, nuclear medicine and medical imaging Method of publishing Open access Institutional support UJF-V - RVO:61389005 UT WOS 000933780800001 EID SCOPUS 85147770583 DOI 10.3390/cancers15030740 Annotation Simple Summary Thyroid carcinoma is the most common cancer of the endocrine system and accounts for 12% of all cancer cases in adolescents in the United States. In this paper, we present a double-blind, randomized, placebo-controlled clinical trial aimed at evaluating the effect of probiotics supplementation in reducing the acute side-effects of radioiodine therapy in DTC patients. The probiotics' effectiveness was confirmed for dry mouth and taste loss or change when it was administered prior to the radioiodine treatment. The benefit was not confirmed for other radiation-induced complications such as pain and swelling in the neck, nausea and vomiting, salivary gland swelling, and diarrhea. Further large-scale clinical trials are warranted to improve our knowledge of this quickly evolving field. Thyroid carcinoma is the most common cancer of the endocrine system, accounting for 12% of all cancer cases in adolescents in the United States. Radioiodine therapy plays a key role in differentiated thyroid cancer (DTC) treatment. This double-blind, randomized, placebo-controlled clinical trial was aimed at evaluating the effect of probiotics supplementation in reducing the acute side-effects of radioiodine therapy in PTC patients. Fifty-six patients were randomly divided into four groups: one placebo and three intervention groups. The probiotics product used in this study was LactoCare (ZistTakhmir Co., Tehran, Iran), a multi-strain commercially available symbiotic containing 12 strains of probiotic species including Lactobacillus strains, Bifidobacteria strains, and Streptococcus thermophilus, plus Fructo-oligosaccharides as the prebiotic. Group 0 was our placebo group (no probiotics), while the other three groups received probiotics capsules for 2/4 days, starting only 2 days prior to radioiodine therapy, only 4 days after radioiodine therapy or 2 days prior and 4 days after radioiodine therapy. Six patients were withdrawn during the study because of poor compliance or at their own request. The symptoms reported by patients including data about the incidence and duration of each complication were recorded. The probiotics' effectiveness was confirmed for dry mouth and taste loss or change when it was administered prior to the radioiodine treatment. The benefit was not confirmed for other radiation-induced complications such as pain and swelling in the neck, nausea and vomiting, salivary gland swelling, and diarrhea. Further large-scale clinical trials are warranted to improve our knowledge in this quickly evolving field. Workplace Nuclear Physics Institute Contact Markéta Sommerová, sommerova@ujf.cas.cz, Tel.: 266 173 228 Year of Publishing 2024 Electronic address https://doi.org/10.3390/cancers15030740
Number of the records: 1